日本的大麻管制法是如何修改的?

IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Yuji Masataka, Yoshiyuki Akahoshi, Munenori Katayama, Futaba Umemura, Naoko Miki, Ryota Nakazawa, Kosuke Shibata, Chikako Yoshida, Ayako Mikami, Toshihiko Matsumoto, Kozo Akino, Ichiro Takumi
{"title":"日本的大麻管制法是如何修改的?","authors":"Yuji Masataka, Yoshiyuki Akahoshi, Munenori Katayama, Futaba Umemura, Naoko Miki, Ryota Nakazawa, Kosuke Shibata, Chikako Yoshida, Ayako Mikami, Toshihiko Matsumoto, Kozo Akino, Ichiro Takumi","doi":"10.1089/can.2025.0006","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> In 2023, Japan's Cannabis Control Act underwent its first major revision since its establishment in 1948. The legal framework surrounding cannabis had long remained rigid, with limited scope for medical or industrial applications. <b>Methods:</b> This review examines the content and implications of the 2023 legal amendments based on governmental documents, legislative records, and secondary analyses of regulatory shifts. The assessment focuses on three key domains: medical application, industrial use, and drug control. <b>Results:</b> Under the revised law, cannabis-derived products intended for medical use were brought under the same regulatory framework as opioid analgesics, theoretically enabling physicians to prescribe them. Simultaneously, the longstanding restriction limiting industrial use to mature stalks and seeds was lifted. However, this liberalization was counterbalanced by the introduction of a stringent THC threshold. On the criminal side, cannabis continues to be regulated as an illicit substance, and new penalties for use have been introduced. The revised law came into effect on December 12, 2024. <b>Conclusion:</b> The 2023 amendment represents a significant shift in Japan's cannabis policy, aiming to balance expanded medical and industrial opportunities with continued drug control. Its practical implications remain to be seen and warrant close monitoring in the coming years.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How Has Japan's Cannabis Control Act Been Amended?\",\"authors\":\"Yuji Masataka, Yoshiyuki Akahoshi, Munenori Katayama, Futaba Umemura, Naoko Miki, Ryota Nakazawa, Kosuke Shibata, Chikako Yoshida, Ayako Mikami, Toshihiko Matsumoto, Kozo Akino, Ichiro Takumi\",\"doi\":\"10.1089/can.2025.0006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> In 2023, Japan's Cannabis Control Act underwent its first major revision since its establishment in 1948. The legal framework surrounding cannabis had long remained rigid, with limited scope for medical or industrial applications. <b>Methods:</b> This review examines the content and implications of the 2023 legal amendments based on governmental documents, legislative records, and secondary analyses of regulatory shifts. The assessment focuses on three key domains: medical application, industrial use, and drug control. <b>Results:</b> Under the revised law, cannabis-derived products intended for medical use were brought under the same regulatory framework as opioid analgesics, theoretically enabling physicians to prescribe them. Simultaneously, the longstanding restriction limiting industrial use to mature stalks and seeds was lifted. However, this liberalization was counterbalanced by the introduction of a stringent THC threshold. On the criminal side, cannabis continues to be regulated as an illicit substance, and new penalties for use have been introduced. The revised law came into effect on December 12, 2024. <b>Conclusion:</b> The 2023 amendment represents a significant shift in Japan's cannabis policy, aiming to balance expanded medical and industrial opportunities with continued drug control. Its practical implications remain to be seen and warrant close monitoring in the coming years.</p>\",\"PeriodicalId\":9386,\"journal\":{\"name\":\"Cannabis and Cannabinoid Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cannabis and Cannabinoid Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/can.2025.0006\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cannabis and Cannabinoid Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/can.2025.0006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:2023年,日本《大麻管制法》自1948年制定以来进行了首次重大修订。关于大麻的法律框架长期以来一直很僵化,医疗或工业应用的范围有限。方法:基于政府文件、立法记录和监管转变的二次分析,对2023年法律修正案的内容和影响进行了研究。评估侧重于三个关键领域:医疗应用、工业用途和药物管制。结果:根据修订后的法律,用于医疗用途的大麻衍生产品被纳入与阿片类镇痛药相同的监管框架,理论上使医生能够开处方。同时,长期以来限制工业使用成熟秸秆和种子的限制也被取消。然而,这种自由化被引入严格的四氢大麻酚门槛所抵消。在刑事方面,大麻继续作为一种非法物质加以管制,并对使用大麻实行了新的惩罚。修订后的法律自2024年12月12日起施行。结论:2023年修正案代表了日本大麻政策的重大转变,旨在平衡扩大的医疗和工业机会与持续的药物管制。其实际影响仍有待观察,需要在未来几年密切监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How Has Japan's Cannabis Control Act Been Amended?

Background: In 2023, Japan's Cannabis Control Act underwent its first major revision since its establishment in 1948. The legal framework surrounding cannabis had long remained rigid, with limited scope for medical or industrial applications. Methods: This review examines the content and implications of the 2023 legal amendments based on governmental documents, legislative records, and secondary analyses of regulatory shifts. The assessment focuses on three key domains: medical application, industrial use, and drug control. Results: Under the revised law, cannabis-derived products intended for medical use were brought under the same regulatory framework as opioid analgesics, theoretically enabling physicians to prescribe them. Simultaneously, the longstanding restriction limiting industrial use to mature stalks and seeds was lifted. However, this liberalization was counterbalanced by the introduction of a stringent THC threshold. On the criminal side, cannabis continues to be regulated as an illicit substance, and new penalties for use have been introduced. The revised law came into effect on December 12, 2024. Conclusion: The 2023 amendment represents a significant shift in Japan's cannabis policy, aiming to balance expanded medical and industrial opportunities with continued drug control. Its practical implications remain to be seen and warrant close monitoring in the coming years.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cannabis and Cannabinoid Research
Cannabis and Cannabinoid Research PHARMACOLOGY & PHARMACY-
CiteScore
6.80
自引率
7.90%
发文量
164
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信